For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

This can occur due to the following scenarios: According to Dr. Harshal Chaudhari - Head Medical Affairs – CM&E Merck Healthcare India Associate Director – Cardiology & Thyroid, Merck ...

German Merck said it plans to combine its scientific ... They will also focus on diabetes, thyroid disorders and cardiovascular diseases, as well as oncology including metastatic colorectal ...